Asset: Potent and selective oral PCSK9 small-molecule inhibitor
Development Stage: IND enabling stage
Indication: Hyperlipidemia
Key Asset Highlights:
- Exhibits high potency and excellent target selectivity against PCSK9, a critical regulator of low-density lipoprotein cholesterol metabolism, with negligible off-target activities to ensure high treatment specificity.
- Effectively blocks PCSK9-mediated degradation of hepatic LDL receptors, significantly reducing serum LDL-C levels and achieving robust lipid-lowering efficacy in preclinical hyperlipidemia models.
- Delivers superior differentiated advantages over traditional injectable PCSK9 monoclonal antibodies, providing an oral administration route that greatly improves patient medication compliance and clinical convenience.
- Demonstrates stable and durable lipid-regulating effects, showing promising therapeutic potential for the long-term management of refractory and persistent hyperlipidemia.
- Possesses favorable oral pharmacokinetic properties and a well-tolerated safety profile, supporting continuous oral administration for chronic metabolic disease intervention.
- Protected by a solid and comprehensive intellectual property portfolio, ensuring stable and exclusive global development and commercialization rights for lipid metabolism disorder treatment.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
